Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index; 15 of the 101 sources its claims cite were checked for support.
Abstract
Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality worldwide. CRC mortality results almost exclusively from metastatic disease (mCRC) for which systemic chemotherapy is often a preferred therapeutic option. Biomarker-based stratification of mCRC enables the use of precision therapy based on individual tumor mutational profiles. Activating mutations in the RAS/RAF/MAPK pathway downstream of EGFR signaling have, until recently, limited the use of EGFR-targeted therapies for mCRC; however, the development of anti-RAS and anti-RAF therapies together with improved strategies to limit compensatory signaling pathways is resulting in improved survival rates in several highly lethal mCRC sub-types (e.g., BRAF-mutant). The use of fluoropyrimidine (FP)-based chemotherapy regimens to treat mCRC continues to evolve contributing to improved long-term survival. Future advances in chemotherapy for mCRC will need to position development relative to the advances made in precision oncology.
Overview
CoChat Summary
TL;DR
This review summarizes recent advances in treating colorectal cancer (CRC), emphasizing biomarker-based stratification and targeted therapies for metastatic CRC (mCRC). It highlights progress in anti-EGFR, anti-RAS, anti-BRAF, anti-VEGF, fluoropyrimidine chemotherapy, and immunotherapy, while noting that mCRC survival remains poor.
Key findings
- CRC causes >930,000 deaths/year worldwide, with >1.9 million new diagnoses annually; by 2040, projections are >3.2 million new cases and >1.6 million deaths. mCRC 5-year survival remains <11%, though median overall survival now exceeds 32 months, improved from 22.6 months in 2012.
- RAS/RAF/MAPK mutations limit EGFR-targeted therapy: KRAS mutations occur in ~40% of mCRC, NRAS in 3–5%, and BRAF in ~8.5%, with BRAFV600E comprising two-thirds of BRAF mutations. BRAFV600E mCRC has median survival of 13.5 months vs. 30.6 months for BRAF wild-type tumors.
- KRASG12C occurs in <4% of mCRC; sotorasib produced objective responses in approximately 10% of patients, and adagrasib showed similar results. In BRAFV600E mCRC, encorafenib plus cetuximab increased objective response rate to 19.5% vs. 1.8% for control, and adding binimetinib increased it to 26.8%.
- Fluoropyrimidine doublets remain central: adding oxaliplatin to 5-FU/LV increased response rate (50.7% vs. 22.3%) and progression-free survival (9.0 vs. 6.2 months), while adding irinotecan improved response rate (49% vs. 31%) and overall survival (17.4 vs. 14.1 months). Immunotherapy is approved for dMMR/MSI-high mCRC, which is <5% of mCRC cases, with some estimates that only 2% of mCRC patients are candidates for successful immune checkpoint blockade.
Methods
- Design: narrative review of therapeutic strategies for CRC, with emphasis on mCRC.
- Data/sample: published literature and clinical trial results; no primary patient cohort or new experimental data are reported.
- Main analysis: narrative synthesis of biomarker-based stratification, targeted therapy development, chemotherapy regimens, and immunotherapy approaches.
Limitations
- Stated: reported survival improvements are often based on clinical trials involving a small percentage of patients, often with favorable performance characteristics; 5-year mCRC survival remains dismal.
- Evident from text: as a narrative review, it does not describe a systematic search strategy, formal quality assessment, or meta-analysis, and it presents no primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
13 Valid · 4 Not valid · 69 Not checked · 19 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Studies combining cetuximab with anti-IGF-1R therapies [54,55] have not yet yielded favorable clinical outcomes that would be consistent with this approach overcoming acquired resistance to anti-EGFR therapy.”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 3. Targeting EGFR in mCRC > 3.3. Alternative Targets in EGFR-Resistant mCRC
What the sources say
- Supportedcites [54] Reidy D.L. Vakiani E. Fakih M.G. Saif M.W. Hecht J.R. Goodman-Davis N. Hollywood E. Shia J. Schwartz J. Chandrawansa K. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer J. Clin. Oncol. 2010 28 4240 4246 10.1200/JCO.2010.30.4154 20713879 PMC3296668 source
In “IMC-A12 in Refractory Anti-EGFR mAb Colorectal Cancer” (page not provided), the authors conclude that IMC-A12 with or without cetuximab was inactive in all but one of 64 patients previously treated with anti-EGFR therapy. The selected group with a prior prolonged anti-EGFR response showed no additional clinical activity, supporting the claim that this combination had not yielded favorable outcomes for overcoming resistance. (LLM, conf=0.92)
- Not checked yetcites [55] Sclafani F. Kim T.Y. Cunningham D. Kim T.W. Tabernero J. Schmoll H.J. Roh J.K. Kim S.Y. Park Y.S. Guren T.K. A Randomized Phase II/III Study of Dalotuzumab in Combination with Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer J. Natl. Cancer Inst. 2015 107 djv258 10.1093/jnci/djv258 26405092 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“precision targeting based on the specific mutational profiles of individual CRC tumors is playing an important role [12].”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 1. Introduction
What the sources say
- Supportedcites [12] Koroukian S.M. Booker B.D. Vu L. Schumacher F.R. Rose J. Cooper G.S. Selfridge J.E. Markt S.C. Receipt of Targeted Therapy and Survival Outcomes in Patients with Metastatic Colorectal Cancer JAMA Netw. Open 2023 6 e2250030 10.1001/jamanetworkopen.2022.50030 36656585 PMC9857024 source
The Introduction (page unavailable) says that molecular profiling informs the choice of targeted therapy for mCRC. The Results (page unavailable) report a clear survival advantage with EGFR inhibitors in patients with RAS-wild-type tumors, supporting the claim's broad point about mutation-guided targeting. The paper notes that survival findings for other targeted therapies were mixed. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent studies with the KRASG12D specific inhibitor MRTX1133 [85] have, however, showed promise that this mutant form of KRAS is also druggable.”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 4. Targeting Mutant KRAS
What the sources say
- Supportedcites [85] Hallin J. Bowcut V. Calinisan A. Briere D.M. Hargis L. Engstrom L.D. Laguer J. Medwid J. Vanderpool D. Lifset E. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor Nat. Med. 2022 28 2171 2182 10.1038/s41591-022-02007-7 36216931 source
The Significance section identifies MRTX1133 as a KRAS G12D-selective inhibitor active in vitro and in vivo, with tumor regression in multiple xenograft models. The Discussion states that these preclinical findings demonstrate the feasibility of developing mutation-selective KRAS G12D inhibitors. This supports the claim that the studies show promise for drugging KRAS G12D; it does not imply clinical efficacy. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple agents targeting both canonical and the β-catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 7. Wnt-Pathway Targeting
What the sources say
- Partly supportedcites [119] Park W.J. Kim M.J. A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities Cells 2023 12 1110 10.3390/cells12081110 37190019 PMC10136927 sourceExperimental — accuracy not yet measured
Section 3.3 says v-ATPase inhibitors are undergoing phase 2 trials, and section 3.1 describes trials of a DKK1 antibody while noting DKK1’s reported connection to non-canonical Wnt signaling. But section 3.2 says the anti-RSPO3 antibody completed its phase 1 trial, not that it is undergoing one. The paper also describes v-ATPase inhibitors as suppressing Wnt/β-catenin signaling, rather than the β-catenin-independent pathway. (LLM, conf=0.85)
- Partly supportedcites [120] Zhao H. Ming T. Tang S. Ren S. Yang H. Liu M. Tao Q. Xu H. Wnt signaling in colorectal cancer: Pathogenic role and therapeutic target Mol. Cancer 2022 21 144 10.1186/s12943-022-01616-7 35836256 PMC9281132 sourceExperimental — accuracy not yet measured
The Drugs and inhibitors section (Tables 2–3; page not provided) describes agents affecting canonical Wnt/β-catenin signaling and lists Box 5 as an inhibitor of Wnt5a-induced signaling. It also describes SM08502 as clinically used for solid tumors. However, the cited passages do not identify v-ATPase inhibitors or anti-RSPO antibodies as agents undergoing clinical trials in CRC or other malignancies. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“while regorafenib whose targets include VEGF-R1, VEGF-R2, and VEGF-R3 or Fruquintinib is used in combination with TAS-102 (combination of trifluridine and Tiperacil) for third-line treatment [128].”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 8. Targeting VEGFR
What the sources say
- Partly supportedcites [128] Li Y. Chen X. Li W. Ye Y. Du X. Sun S. Liu L. Zhang H. Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review Front. Oncol. 2021 11 684309 10.3389/fonc.2021.684309 34109130 PMC8180844 sourceExperimental — accuracy not yet measured
The Introduction and ‘Current Status of the Third-Line Regimen’ (page not supplied) identify regorafenib, fruquintinib, and TAS-102 as third-line treatments for mCRC. They do not say that regorafenib or fruquintinib is used in combination with TAS-102; the paper discusses them as separate options. The Current Status section does support the cited sentence’s VEGFR1/2/3 targets for regorafenib. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims · 2 with their cited sources checked
Create a free account to see all 105 claims and to verify the 86 references still open.
- It may state two separate claims as one. 52
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This type of targeted therapy is only effective in the absence of mutations in the RAS and BRAF genes.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors are widely used to treat melanoma with BRAF-V600 mutations, and encorafenib is also approved, in combination with cetuximab, for metastatic CRC with BRAF-V600E mutation, which is the predominant BRAF mutation in CRC [29].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, acquired resistance to BRAF-targeted therapies in BRAF-mutated CRC is a significant challenge, but it may potentially be overcome using combinations of anti-BRAF and anti-EGFR therapies with inhibitors of MEK, Wnt, or cyclin-dependent kinases CDK4/6 [29].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Activating mutations in the RAS/RAF/MEK/ERK signaling pathway downstream of EGFR generally confer resistance to anti-EGFR therapies; however, recent developments have led to new approaches for therapeutically targeting CRC with RAS or BRAF mutations [29].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“For instance, a combination of anti-EGFR therapy with a MEK inhibitor, such as selumetinib or pimasertib, could potentially limit acquired resistance to anti-EGFR antibody therapy from activating mutations in RAS or BRAF [29].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 3. Targeting EGFR in mCRC
“The formation of either homo- or heterodimers is possible resulting in 28 possible combinations”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 3. Targeting EGFR in mCRC
“The EGFR family includes HER2/Neu/ERBB2, HER3/ERBB3, and HER4/ERBB4 in addition to EGFR/ErbB1/HER1.”
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“Approaches for precision targeting of mCRC sub-types derive from an understanding of colorectal carcinogenesis initiated in the pioneering work of Fearon and Vogelstein [17].”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
Background5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“5-Fluororuracil (5-FU) was introduced into the clinic >60 years ago, and its use in the adjuvant setting in combination with folinic acid (leucovorin (LV)) was shown to decrease the risk for disease recurrence for patients with primary colon cancer [8,9].”
Backgroundde Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“%) and longer time to progression (6.7 vs. 4.4 months), but, in this case, overall survival benefit was significantly increased (17.4 vs. 14.1 months) [140].”
BackgroundInfluentialTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“The alternative FP doublet therapy is often used for second-line treatment following disease progression (e.g., FOLFOX (1st) → FOLFIRI (2nd)), and there is no evidence for a preferred sequencing of these regimens [141].”
BackgroundGlobal burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN
Morgan, E., Arnold, M., Gini, A., Lorenzoni, V, Cabasag, C. J., Laversanne, M., Vignat, J., Ferlay, J., Murphy, N., & Bray, F. (2023) · Gut · doi:10.1136/gutjnl-2022-327736 · Cited by 2,429 · cited 1×
“CRC collectively is a leading cause of cancer-related mortality worldwide resulting in >930,000 deaths [1].”
BackgroundGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“Consistent with BRAF V600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAF V600E tumors as single agents [93] or in combination with chemotherapy [94].”
BackgroundEpidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027 · cited 2×
“Epidermal growth in CRC, and its EGFR signaling amphiregulin ( transautophos-phorylation [26 HER4/ERBB4 heterodimers is pathways collectively promote binding promotes HER2/HER3 and HER3/HER4 heterodimers are tumor promoting [27].”
BackgroundImmunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954 · cited 1×
“Improvements in precision oncology for mCRC are augmenting gains achieved through the introduction of immunotherapy [15] and improved surgical techniques that collectively are contributing toward improved long-term survival for distinct sub-types of mCRC [16].”
BackgroundEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 1×
“Improved survival using targeted therapies has resulted from not only the discovery of new drugs that target actionable driver mutations but also the elucidation of the mechanisms for compensatory signaling pathways that are activated in response to target inhibition [14].”
BackgroundFalcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crinò, L., Benedetti, G., Evangelista, W., Fanchini, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0928 · Cited by 1,241 · cited 1×
“For patients deemed able to tolerate more aggressive therapy, the inclusion of both irinotecan and oxaliplatin together with 5-FU/LV in FOLFOXFIRI triplet chemotherapy improved ORR, PFS, and median OS relative to doublet therapy [142].”
BackgroundKRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127 · cited 1×
“Studies in recent years have, for the first time, demonstrated the feasibility and clinical utility of directly targeting mutant KRAS with small molecule therapeutics designed to exploit specific structural features present only in the mutant protein [76] (Table 1).”
BackgroundSartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956 · cited 1×
“5-FU-based chemotherapy is central to systemic therapy for mCRC [136] (Figure 3).”
BackgroundBertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 2×
“…cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32]. associated with reduced efficacy of anti-EGFR therapy [31], and >36% of cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32].”
BackgroundThe Chromosomal Instability Pathway in Colon Cancer
Pino, M. S., & Chung, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.065 · Cited by 932 · cited 1×
“CIN involves an accelerated rate in either gain or loss of large parts or entire chromosomes or chromosomal rearrangements [19] with 17 sub-types of CIN identified in a pan-cancer analysis [20].”
BackgroundClinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M. T. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.004 · Cited by 858 · cited 1×
“BRAF mutations occur in ~8.5% of CRC cases [88] with BRAF V600E , a class I BRAF mutation and the predominant mutation comprising two-thirds of all BRAF mutations in CRC. Class I BRAF mutations enable BRAF to signal as a monomer and independent of upstream input or RAS activation [89].”
BackgroundInfluentialWnt signaling in colorectal cancer: Pathogenic role and therapeutic target
Zhao, H., Ming, T., Tang, S., Ren, S., Yang, H., Liu, M., Tao, Q., & Xu, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01616-7 · Cited by 857 · cited 1×
“Multiple agents targeting both canonical and the β -catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
BackgroundPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 1×
“Inhibition of BRAF V600E with vemurafenib [96] or dabrafenib [97] has limited activity in mCRC even when combined with anti-MEK therapy with trametinib.”
BackgroundFrom tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654 · cited 1×
“5-FU/LV is useful in palliative therapy for mCRC, but the development of effective doublet combination therapy regimens, including FOLFOX (folinic acid (leucovorin), 5-FU, oxaliplatin) and FOLFIRI (leucovorin, 5-FU, irinotecan) [10], resulted in significant survival advantages.”
BackgroundPathways of Colorectal Carcinogenesis
Nguyen, L. H., Goel, A., & Chung, D. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.08.059 · Cited by 606 · cited 2×
“%) alternative pathways of CRC carcinogenesis [18].”
BackgroundTabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553 · cited 1×
“Recent studies with the KRAS G12D specific inhibitor MRTX1133 [85] have, however, showed promise that this mutant form of KRAS is also druggable.”
BackgroundAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527 · cited 2×
“Sotorasib and adagrasib both displayed increased activity in combination with panitumumab [83] (CODEBREAK 300, NCT05198934) and cetuximab [84] (KRYSTAL-1, NCT03785249), respectively.”
BackgroundResistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · cited 1×
“Progressive disease following anti-EGFR therapy may result from acquired resistance [45,46], which may result from any one of several causes [47].”
BackgroundMontagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · cited 1×
“The S492R mutation is selective for resistance to cetuximab, and treatment with panitumumab may be an option for patients with this EGFR mutation [48].”
BackgroundCorcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507 · cited 1×
“Inhibition of BRAF V600E with vemurafenib [96] or dabrafenib [97] has limited activity in mCRC even when combined with anti-MEK therapy with trametinib.”
BackgroundEGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504 · cited 1×
“The rationale for combining selective KRAS MT inhibition therapy with anti-EGFR therapy is that adaptive feedback mediated by EGFR may stimulate the RAS/MAPK pathway [82].”
BackgroundPietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486 · cited 1×
“Consistent with BRAF V600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAF V600E tumors as single agents [93] or in combination with chemotherapy [94].”
BackgroundEGFR/Ras/MAPK Signaling Mediates Adult Midgut Epithelial Homeostasis and Regeneration in Drosophila
Jiang, H., Grenley, M. O., Bravo, M.-J., Blumhagen, R. Z., & Edgar, B. A. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.026 · Cited by 467 · cited 1×
“EGFR plays an important role in normal colon development [22], and it is an important target for treatment of mCRC in which the RAS/RAF/MEK pathway is not activated through mutation (Figure 1).”
BackgroundSotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398 · cited 1×
“Sotorasib and adagrasib both displayed increased activity in combination with panitumumab [83] (CODEBREAK 300, NCT05198934) and cetuximab [84] (KRYSTAL-1, NCT03785249), respectively.”
BackgroundStanding the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388 · cited 1×
“5-Fluororuracil (5-FU) was introduced into the clinic >60 years ago, and its use in the adjuvant setting in combination with folinic acid (leucovorin (LV)) was shown to decrease the risk for disease recurrence for patients with primary colon cancer [8,9].”
BackgroundAdjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
Baxter, N. N., Kennedy, E. B., Bergsland, E., Berlin, J., George, T. J., Gill, S., Gold, P. J., Hantel, A., Jones, L., Lieu, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02538 · Cited by 367 · cited 1×
“Factors associated with high risk for stage IIA (T3) disease include sampling 12 lymph nodes in the surgical specimen, an undifferentiated tumor grade, and perineural or lymphovascular invasion [132].”
BackgroundExploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355 · cited 2×
“MSI-high or dMMR mCRC patients favorably respond to immune checkpoint blockade (ICB), and this is now the preferred front-line treatment [129].”
BackgroundVan der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
Ou, S.-H. I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Bazhenova, L., Johnson, M. L., Velastegui, K. L., Cilliers, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02752 · Cited by 322 · cited 1×
“Similar results were obtained with the KRAS G12C -targeted therapy ada-grasib (MRTX849, Mirati) in clinical studies for mCRC [81].”
ResultFakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00605-7 · Cited by 320 · cited 1×
“In a Phase 2 study, Sotorasib (AMG510, Amgen), a selective KRAS G12C inhibitor, displayed activity in mCRC patients expressing the target mutation with approximately 10% of patients displaying an objective response [80].”
BackgroundInnocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01798 · Cited by 317 · cited 3×
“KRAS G12D mutation is relatively more frequent than KRAS G12C in mCRC, particularly in black patients (13% vs. 6% in white patients) [4].”
BackgroundInfluentialIncreased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B., Egyhazi, S., Hansson, J., Wu, H., King, A. J., Van Belle, P., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 309 · cited 1×
“Amplification of cyclin D1 and mutation in CDK4/6 and other CDKs are associated with resistance to BRAF inhibitors [100], and inclusion of CDK inhibitors, including CDK12 [101], which is activated via the RAS/MAPK pathway, with anti-BRAF therapy is being investigated for overcoming resistance to…”
BackgroundWang, J., Li, S., Liu, Y., Zhang, C., Li, H., & Lai, B. (2020) · Cancer Medicine · doi:10.1002/cam4.2673 · Cited by 308 · cited 2×
“Consistent with this, 5-year survival rates in mCRC remain dismal [6] indicating a great need for further therapeutic advances.”
BackgroundA pan-cancer compendium of chromosomal instability
Drews, R. M., Hernando, B., Tarabichi, M., Haase, K., Lesluyes, T., Smith, P. S., Morrill Gavarró, L., Couturier, D.-L., Liu, L., Schneider, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04789-9 · Cited by 294 · cited 1×
“CIN involves an accelerated rate in either gain or loss of large parts or entire chromosomes or chromosomal rearrangements [19] with 17 sub-types of CIN identified in a pan-cancer analysis [20].”
BackgroundDevelopment of Farnesyl Transferase Inhibitors: A Review
Appels, N. M. G. M., Beijnen, J. H., & Schellens, J. H. M. (2005) · The Oncologist · doi:10.1634/theoncologist.10-8-565 · Cited by 272
Osada, T., Chen, M., Yang, X. Y., Spasojevic, I., Vandeusen, J. B., Hsu, D., Clary, B. M., Clay, T. M., Chen, W., Morse, M. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3978 · Cited by 271 · cited 1×
“Other modulators of canonical Wnt signaling include niclosamide that decreases Dv1-2 and β -catenin expression [114] and now is in clinical trials for CRC [115].”
BackgroundWNT as a Driver and Dependency in Cancer
Parsons, M. J., Tammela, T., & Dow, L. E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0190 · Cited by 257 · cited 1×
“…Wnt/ β -catenin pathway also plays a critical role in maintaining the cancer stem cell (CSC) population in malignant tissues making Wnt a potential target in CRC [109], even though its essential role in normal intestine function makes toxicity of agents targeting the Wnt pathway a serious concern.”
BackgroundZhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · cited 1×
“Progressive disease following anti-EGFR therapy may result from acquired resistance [45,46], which may result from any one of several causes [47].”
BackgroundCremolini, C., Antoniotti, C., Stein, A., Bendell, J., Gruenberger, T., Rossini, D., Masi, G., Ongaro, E., Hurwitz, H., Falcone, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01225 · Cited by 235 · cited 1×
“The increased aggressiveness of BRAF V600E mCRC led to evaluation of more aggressive first-line chemotherapy; however, triplet therapy with FOLFOXIRI did not demonstrate an advantage relative to doublet therapy (FOLFOX or FOLFIRI) with bevacizumab [92].”
BackgroundPfeiffer, P., Yilmaz, M., Möller, S., Zitnjak, D., Krogh, M., Petersen, L. N., Poulsen, L. Ø., Winther, S. B., Thomsen, K. G., & Qvortrup, C. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30827-7 · Cited by 232 · cited 1×
“The more recent introduction of TAS-102 (trifluridine-tipiracil) [149] is further extending the survival of patients in third-line treatment.”
BackgroundNakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231 · cited 1×
“Combining pertuzumab, a mAb that prevents HER2/HER3 dimer formation, with trastuzumab also shows promise in combination for this indication [35].”
BackgroundAdjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.075 · Cited by 219 · cited 1×
“…strategies, including inhibiting post-translational modification of KRAS using farnesyl transferase inhibitors (FTI [70], e.g., tipifarnib [71] and salirasib [72]) to prevent localization to the inner plasma membrane, did not, however, evoke objective responses in clinical trials,…”
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215 · cited 1×
“[21].”
Gong, J., Wang, C., Lee, P. P., Chu, P., & Fakih, M. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0016 · Cited by 207 · cited 1×
“…for ICB therapy in MSS mCRC is considered to result from a relatively lower tumor mutational burden (TMB) reducing the presentation of neo-antigens. mCRC that originates via Pol epsilon mutations displays relatively higher TMB, and these patients show increased response to ICB therapy [146].”
BackgroundZhang, F. L., Kirschmeier, P., Carr, D., James, L., Bond, R. W., Wang, L., Patton, R., Windsor, W. T., Syto, R., Zhang, R., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.15.10232 · Cited by 197 · cited 1×
“…using farnesyl transferase inhibitors (FTI [70], e.g., tipifarnib [71] and salirasib [72]) to prevent localization to the inner plasma membrane, did not, however, evoke objective responses in clinical trials, possibly due to activation of a bypass prenylation pathway via geranylgeranylation [73].”
BackgroundSurvival improvement for patients with metastatic colorectal cancer over twenty years
Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00353-4 · Cited by 192 · cited 3×
“The overall percent of mCRC patients treated with FOLFOX or FOLFIRI has not diminished even as the introduction of targeted therapies since 2012 has improved OS [11].”
BackgroundInfluentialFang, L., Zhu, Q., Neuenschwander, M., Specker, E., Wulf-Goldenberg, A., Weis, W. I., von Kries, J. P., & Birchmeier, W. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1519 · Cited by 190 · cited 1×
“Recently, niclosamide and two other β -catenin inhibitors (FH535 [116] and LF3 [117]) have been shown to downregulate MACC1-regulated S100A4 expression to decrease CRC propensity for metastatic progression [118].”
BackgroundRising Proportion of Young Individuals With Rectal and Colon Cancer
Kasi, P. M., Shahjehan, F., Cochuyt, J. J., Li, Z., Colibaseanu, D., & Merchea, A. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.10.002 · Cited by 185 · cited 1×
“CRC is also increasingly being diagnosed in younger individuals [3] with >20% of new CRC cases now diagnosed in individuals 55 years or younger.”
BackgroundA small-molecule inhibitor of Tcf/β-catenin signaling down-regulates PPARγ and PPARδ activities
Handeli, S., & Simon, J. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2063 · Cited by 183 · cited 1×
“Recently, niclosamide and two other β -catenin inhibitors (FH535 [116] and LF3 [117]) have been shown to downregulate MACC1-regulated S100A4 expression to decrease CRC propensity for metastatic progression [118].”
BackgroundRoss, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177 · cited 1×
“Targeting mutant KRAS at the mRNA or gene level is also under investigation; a 16mer antisense oligonucleotide (AZD4785) targeting the 3 ′ -untranslated region was evaluated in a Phase 1 clinical trial, but no follow-up studies are yet reported [75].”
BackgroundEttrich, T. J., & Seufferlein, T. (2018) · Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_3 · Cited by 175 · cited 1×
“…inhibitor targeting EGFR1-3, TIE2 (angiopoietin receptor), platelet-derived growth factor receptor β (PDGFR-β ), FGFR, KIT, RET, and BRAF [56], is approved for the treatment of refractory mCRC [57] and, in combination with cetuximab, displays potential for overcoming acquired resistance…”
BackgroundNash, G. M., Gimbel, M., Shia, J., Nathanson, D. R., Ndubuisi, M. I., Zeng, Z.-S., Kemeny, N., & Paty, P. B. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0605-3 · Cited by 172 · cited 1×
“In general, activating KRAS mutations in mCRC are associated with accelerated metastatic progression [67] and relatively poor outcomes with G12S mutations associated with a particularly high mortality rate [68].”
BackgroundThe current understanding on the impact of KRAS on colorectal cancer
Meng, M., Zhong, K., Jiang, T., Liu, Z., Kwan, H. Y., & Su, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111717 · Cited by 171 · cited 1×
“%) also occur [66].”
Histone demethylase KDM5D upregulation drives sex differences in colon cancer
Li, J., Lan, Z., Liao, W., Horner, J. W., Xu, X., Liu, J., Yoshihama, Y., Jiang, S., Shim, H. S., Slotnik, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06254-7 · Cited by 171 · cited 1×
“CRC is also a malignancy associated with serious health disparities related to both race [4] and gender [5].”
BackgroundTargeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Porru, M., Pompili, L., Caruso, C., Biroccio, A., & Leonetti, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0719-1 · Cited by 170 · cited 1×
“Despite the prevalence of activating KRAS mutation in CRC and its importance for determining the choice of therapy in mCRC [65], until recently, no drugs were available to directly target mutant KRAS.”
BackgroundTNIK inhibition abrogates colorectal cancer stemness
Masuda, M., Uno, Y., Ohbayashi, N., Ohata, H., Mimata, A., Kukimoto-Niino, M., Moriyama, H., Kashimoto, S., Inoue, T., Goto, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms12586 · Cited by 168 · cited 1×
“…activation in CRC etiology, cancer therapeutic development targeting the Wnt pathway is focused on downstream mediators including tumor necrosis factor receptor-associated factor (TRAF) and NCK-interacting protein kinase (TNIK), an essential regulator of the TCF4/ β -catenin complex [110].”
BackgroundA Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Riely, G. J., Johnson, M. L., Medina, C., Rizvi, N. A., Miller, V. A., Kris, M. G., Pietanza, M. C., Azzoli, C. G., Krug, L. M., Pao, W. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318223c099 · Cited by 168 · cited 1×
“…including inhibiting post-translational modification of KRAS using farnesyl transferase inhibitors (FTI [70], e.g., tipifarnib [71] and salirasib [72]) to prevent localization to the inner plasma membrane, did not, however, evoke objective responses in clinical trials, possibly due to activation…”
BackgroundIdentification of pyrazolopyridazinones as PDEδ inhibitors
Papke, B., Murarka, S., Vogel, H. A., Martín-Gago, P., Kovacevic, M., Truxius, D. C., Fansa, E. K., Ismail, S., Zimmermann, G., Heinelt, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11360 · Cited by 160 · cited 1×
“Alternative therapeutic approaches include inhibiting the interaction of farnesylated KRAS with cGMP phosphodiesterase delta (PDE δ ) using small molecule inhibitors including deltarasin; however, this approach is not selective for cancer cells and causes systemic toxicities [74].”
BackgroundAcquired resistance to EGFR‐targeted therapies in colorectal cancer
Van Emburgh, B. O., Sartore-Bianchi, A., Di Nicolantonio, F., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 160
Tevaarwerk, A. J., & Kolesar, J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.029 · Cited by 150 · cited 1×
“Lapatanib [33], a small molecule inhibitor of EGFR and HER2, also shows promising activity in combination with trastuzumab for the treat-ment of HER2-overexpressed mCRC [34].”
BackgroundPIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Wang, Q., Shi, Y.-L., Zhou, K., Wang, L.-L., Yan, Z.-X., Liu, Y.-L., Xu, L.-L., Zhao, S.-W., Chu, H.-L., Shi, T.-T., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0776-6 · Cited by 147 · cited 1×
“Mutations in the PI3K/AKT/mTOR pathway are common in mCRC [102], contribute to malignant transformation [103], and are implicated in resistance to front-line therapy [104].”
BackgroundRegulation of Wnt/β‐catenin signalling by tankyrase‐dependent poly(ADP‐ribosyl)ation and scaffolding
Mariotti, L., Pollock, K., & Guettler, S. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14038 · Cited by 144 · cited 1×
“A Tankyrase inhibitor, IWR-1 [112], also shows promise in targeting CSCs by modulating PARylation of AXIN, a key component of both the β -catenin destruction complex and the WNT signalosome [113].”
BackgroundReidy, D. L., Vakiani, E., Fakih, M. G., Saif, M. W., Hecht, J. R., Goodman-Davis, N., Hollywood, E., Shia, J., Schwartz, J., Chandrawansa, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.4154 · Cited by 138 · cited 1×
“Studies combining cetuximab with anti-IGF-1R therapies [54,55] have not yet yielded favorable clinical outcomes that would be consistent with this approach overcoming acquired resistance to anti-EGFR therapy.”
BackgroundGmeiner, W. H., & Okechukwu, C. C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.136 · Cited by 133 · cited 1×
“The dismal 5-year survival rate for mCRC represents a substantial improvement relative to the survival rate before the introduction and optimization of fluoropyrimidine (FP) chemotherapy [7].”
BackgroundSelf-citationIshaque, N., Abba, M. L., Hauser, C., Patil, N., Paramasivam, N., Huebschmann, D., Leupold, J. H., Balasubramanian, G. P., Kleinheinz, K., Toprak, U. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07041-z · Cited by 132 · cited 1×
“Mutations in the PI3K/AKT/mTOR pathway are common in mCRC [102], contribute to malignant transformation [103], and are implicated in resistance to front-line therapy [104].”
BackgroundFakih, M., Sandhu, J. S., Lim, D. W., Li, X., Li, S., & Wang, C. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7845 · Cited by 130 · cited 1×
“…EGFR1-3, TIE2 (angiopoietin receptor), platelet-derived growth factor receptor β (PDGFR-β ), FGFR, KIT, RET, and BRAF [56], is approved for the treatment of refractory mCRC [57] and, in combination with cetuximab, displays potential for overcoming acquired resistance to anti-EGFR therapy [58].”
BackgroundThe role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
Yaeger, R., Kotani, D., Mondaca, S., Parikh, A. R., Bando, H., Van Seventer, E. E., Taniguchi, H., Zhao, H., Thant, C. N., de Stanchina, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2004 · Cited by 125 · cited 1×
“Class II BRAF mutations also display limited response to anti-EGFR therapy, while class III BRAF mutations, which are dependent on upstream input for signaling, are responsive to anti-EGFR therapy [95].”
BackgroundOddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121 · cited 1×
“…the cause for the lack of efficacy for drugs that directly target mutant BRAF V600E to be ineffective in mCRC with this activating mutation, and acquired resistance to anti-BRAF V600E therapy is associated with EGFR mutations and amplification and activating RAS or alternative BRAF mutations [98].”
BackgroundYakirevich, E., Resnick, M. B., Mangray, S., Wheeler, M., Jackson, C. L., Lombardo, K. A., Lee, J., Kim, K.-M., Gill, A. J., Wang, K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3000 · Cited by 121 · cited 1×
“Tumors expressing the fusion gene protein products benefit from treatment with ALK inhibitors such as ceritinib [63] or NTRK inhibitors such as larotrectinib or entrectinib [64].”
BackgroundLi, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119 · cited 2×
“Elevated plasma levels of EGFR ligands such as epiregulin (EREG) and amphiregulin (AREG) may be indicative of resistance to anti-EGFR Cetuximab and panitumumab treatment results in similar survival benefit. anti-EGFR therapy [29].”
BackgroundBurock, S., Daum, S., Keilholz, U., Neumann, K., Walther, W., & Stein, U. (2018) · BMC Cancer · doi:10.1186/s12885-018-4197-9 · Cited by 117 · cited 1×
“Other modulators of canonical Wnt signaling include niclosamide that decreases Dv1-2 and β -catenin expression [114] and now is in clinical trials for CRC [115].”
BackgroundMartins-Neves, S. R., Paiva-Oliveira, D. I., Fontes-Ribeiro, C., Bovée, J. V. M. G., Cleton-Jansen, A.-M., & Gomes, C. M. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.004 · Cited by 115
HER3 in cancer: from the bench to the bedside
Gandullo‐Sánchez, L., Ocaña, A., & Pandiella, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02515-x · Cited by 115
Van Schaeybroeck, S., Kalimutho, M., Dunne, P. D., Carson, R., Allen, W., Jithesh, P. V., Redmond, K. L., Sasazuki, T., Shirasawa, S., Blayney, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.032 · Cited by 106
Salem, M. E., El-Refai, S. M., Sha, W., Puccini, A., Grothey, A., George, T. J., Hwang, J. J., O'Neil, B., Barrett, A. S., Kadakia, K. C., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00245 · Cited by 101 · cited 1×
“In contrast to lung adenocarcinoma, in which it is present in 11% of cases [77], KRAS G12C occurs in 4% of mCRC cases [78].”
BackgroundDirect Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Reita, D., Pabst, L., Pencreach, E., Guérin, E., Dano, L., Rimelen, V., Voegeli, A.-C., Vallat, L., Mascaux, C., & Beau-Faller, M. (2022) · Cancers · doi:10.3390/cancers14051321 · Cited by 95 · cited 1×
“In contrast to lung adenocarcinoma, in which it is present in 11% of cases [77], KRAS G12C occurs in 4% of mCRC cases [78].”
BackgroundArena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5640 · Cited by 93 · cited 1×
“Monoclonal antibodies that bind different epitopes of EGFR, including Sym004 [49], which is a combination of two mAbs that target EGFR extracellular domain III, and MM-151 [50], have the potential to overcome these forms of acquired resistance to cetuximab or panitumumab.”
BackgroundSclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W., Tabernero, J., Schmoll, H. J., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv258 · Cited by 92 · cited 1×
“Studies combining cetuximab with anti-IGF-1R therapies [54,55] have not yet yielded favorable clinical outcomes that would be consistent with this approach overcoming acquired resistance to anti-EGFR therapy.”
BackgroundBRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
Ciombor, K. K., Strickler, J. H., Bekaii-Saab, T. S., & Yaeger, R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02541 · Cited by 92 · cited 2×
“BRAF mutations occur in ~8.5% of CRC cases [88] with BRAF V600E , a class I BRAF mutation and the predominant mutation comprising two-thirds of all BRAF mutations in CRC. Class I BRAF mutations enable BRAF to signal as a monomer and independent of upstream input or RAS activation [89].”
BackgroundInfluentialCassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr031 · Cited by 90 · cited 1×
“Capecitabine, an oral FP that is enzymatically converted to 5-FU, was shown to be equivalent to 5-FU in survival benefit [138].”
BackgroundStrategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82 · cited 1×
“Progressive disease following anti-EGFR therapy may result from acquired resistance [45,46], which may result from any one of several causes [47].”
BackgroundSym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
Iida, M., Brand, T. M., Starr, M. M., Li, C., Huppert, E. J., Luthar, N., Pedersen, M. W., Horak, I. D., Kragh, M., & Wheeler, D. L. (2013) · Neoplasia · doi:10.1593/neo.131584 · Cited by 75 · cited 1×
“Monoclonal antibodies that bind different epitopes of EGFR, including Sym004 [49], which is a combination of two mAbs that target EGFR extracellular domain III, and MM-151 [50], have the potential to overcome these forms of acquired resistance to cetuximab or panitumumab.”
BackgroundThe Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
Coleman, N., Moyers, J. T., Harbery, A., Vivanco, I., & Yap, T. A. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s305068 · Cited by 71 · cited 1×
“However, targeting of the PI3K/AKT/mTOR pathway has not yet proven to be a successful strategy for treating mCRC [105], although this remains an area of investigation.”
BackgroundThe Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
Lucas, L. M., Dwivedi, V., Senfeld, J. I., Cullum, R. L., Mill, C. P., Piazza, J. T., Bryant, I. N., Cook, L. J., Miller, S. T., Lott, J. H., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000381 · Cited by 70 · cited 1×
“…HER3 as a target such as istiratumab, which binds HER3 and insulin-like growth factor 1 receptor (IGF-1R) [42], also display promise for CRC. HER4 is also expressed in mCRC, and, paradoxically, it may act as either a tumor suppressor or an oncoprotein depending on its dimerization status [43].”
BackgroundCurrent Surgical Management Strategies for Colorectal Cancer Liver Metastases
Ivey, G. D., Johnston, F. M., Azad, N. S., Christenson, E. S., Lafaro, K. J., & Shubert, C. R. (2022) · Cancers · doi:10.3390/cancers14041063 · Cited by 70
A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
Mota, J. M., Collier, K. A., Barros Costa, R. L., Taxter, T., Kalyan, A., Leite, C. A., Chae, Y. K., Giles, F. J., & Carneiro, B. A. (2017) · Oncotarget · doi:10.18632/oncotarget.18467 · Cited by 69 · cited 2×
“Epidermal growth in CRC, and its EGFR signaling amphiregulin ( transautophos-phorylation [26 HER4/ERBB4 heterodimers is pathways collectively promote binding promotes HER2/HER3 and HER3/HER4 heterodimers are tumor promoting [27].”
BackgroundWang, H., Li, Z., Ou, Q., Wu, X., Nagasaka, M., Shao, Y., Ou, S. I., & Yang, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.4561 · Cited by 64 · cited 1×
“Tumors expressing the fusion gene protein products benefit from treatment with ALK inhibitors such as ceritinib [63] or NTRK inhibitors such as larotrectinib or entrectinib [64].”
BackgroundRal signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58 · cited 1×
“RALA and RALB are upregulated in CRC [106] and are implicated in invasion and metastasis in pancreatic cancer, but analogous roles in CRC have not been reported [107].”
BackgroundA New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Park, W.-J., & Kim, M. J. (2023) · Cells · doi:10.3390/cells12081110 · Cited by 57 · cited 1×
“Multiple agents targeting both canonical and the β -catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
BackgroundDeming, D. A., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Eickhoff, J. C., Kolesar, J. M., Fioravanti, S., Greten, T. F., Compton, K., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-015-0314-7 · Cited by 52 · cited 1×
“Combining anti-EGFR therapy with a MEK inhibitor (e.g., selumetinib [60] or pimasertib [61]) may hold therapeutic promise in limiting resistance via this mechanism.”
BackgroundLédel, F., Hallström, M., Ragnhammar, P., Öhrling, K., & Edler, D. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.008 · Cited by 52 · cited 1×
“HER3 is widely expressed in mCRC, and elevated HER3 expression was shown to be an independent prognostic factor that was associated with poor outcomes [37].”
BackgroundGandini, A., Puglisi, S., Pirrone, C., Martelli, V., Catalano, F., Nardin, S., Seeber, A., Puccini, A., & Sciallero, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1161048 · Cited by 42 · cited 1×
“Clinical studies have investigated the potential of chemotherapy to improve the activity of immunotherapy in MSS mCRC, but no therapeutic benefit has been established for this approach [148].”
BackgroundUlivi, P., Scarpi, E., Chiadini, E., Marisi, G., Valgiusti, M., Capelli, L., Casadei Gardini, A., Monti, M., Ruscelli, S., Frassineti, G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061240 · Cited by 42 · cited 1×
“In front-line treatment for mCRC, anti-VEGF therapy was shown to be comparable with anti-EGFR therapy when either was combined with chemotherapy [126], and while some previous studies indicated that chemotherapy was more effective in right-sided CRC [127], no side dependence was detected.”
ResultMartinelli, E., Cremolini, C., Mazard, T., Vidal, J., Virchow, I., Tougeron, D., Cuyle, P., Chibaudel, B., Kim, S. C. H., Ghanem, I., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100603 · Cited by 42 · cited 1×
“Front-line chemotherapy for BRAF V600E mCRC is not firmly established but frequently consists of doublet therapy (FOLFOX or FOLFIRI) in combination with targeted therapy (e.g., bevacizumab) [90].”
BackgroundCDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
Houles, T., Lavoie, G., Nourreddine, S., Cheung, W., Vaillancourt-Jean, É., Guérin, C. M., Bouttier, M., Grondin, B., Lin, S., Saba-El-Leil, M. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34179-8 · Cited by 40 · cited 1×
“…D1 and mutation in CDK4/6 and other CDKs are associated with resistance to BRAF inhibitors [100], and inclusion of CDK inhibitors, including CDK12 [101], which is activated via the RAS/MAPK pathway, with anti-BRAF therapy is being investigated for overcoming resistance to targeted therapy in…”
BackgroundSlater, S., Bryant, A., Chen, H.-C., Begum, R., Rana, I., Aresu, M., Peckitt, C., Zhitkov, O., Lazaro-Alcausi, R., Borja, V., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10699-4 · Cited by 37 · cited 1×
“Circulating tumor DNA (ctDNA) is emerging as a predictive factor for the necessity of adjuvant chemotherapy, and the use of ctDNA is expected to inform standard practice in the near future, potentially reducing toxicity due to unnecessary chemotherapy [134,135].”
BackgroundClifton, K., Rich, T. A., Parseghian, C., Raymond, V. M., Dasari, A., Pereira, A. A. L., Willis, J., Loree, J. M., Bauer, T. M., Chae, Y. K., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00141 · Cited by 37 · cited 1×
“Resistance to anti-EGFR therapy also occurs in mCRC expressing ALK fusions (0.2% of cases) or neurotrophic tyrosine receptor kinase ( NTRK) fusions (0.7%), and these may be detected through sequencing circulating tumor DNA (ctDNA) [62].”
BackgroundInfluentialBekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad200 · Cited by 36
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 36 · cited 1×
“Challenges in targeting KRAS through direct targeting of the GTP binding pocket include the high affinity for its native substrate GTP, which is abundant in cancer cells [69].”
BackgroundDifferential involvement of RalA and RalB in colorectal cancer
Martin, T. D., & Der, C. J. (2012) · Small GTPases · doi:10.4161/sgtp.19571 · Cited by 36 · cited 1×
“RALA and RALB are upregulated in CRC [106] and are implicated in invasion and metastasis in pancreatic cancer, but analogous roles in CRC have not been reported [107].”
BackgroundAtreya, C. E., Yaeger, R., & Chu, E. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175679 · Cited by 35 · cited 1×
“Furthermore, an improved surgical resection rate was found with triplet therapy [143].”
BackgroundLoupakis, F., Cremolini, C., Fioravanti, A., Orlandi, P., Salvatore, L., Masi, G., Schirripa, M., Di Desidero, T., Antoniotti, C., Canu, B., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-013-0284-7 · Cited by 33 · cited 1×
“Elevated levels of EGF and other EGFR ligands (e.g., TGF-α , epiregulin (EREG), and AREG) also are indicative of decreased probability of anti-EGFR efficacy [44].”
BackgroundAzadi, A., Golchini, A., Delazar, S., Kahaki, F. A., Dehnavi, S. M., Payandeh, Z., & Eyvazi, S. (2021) · Biological Procedures Online · doi:10.1186/s12575-021-00147-7 · Cited by 33 · cited 1×
“Multi-targeting antibodies that include HER3 as a target such as istiratumab, which binds HER3 and insulin-like growth factor 1 receptor (IGF-1R) [42], also display promise for CRC. HER4 is also expressed in mCRC, and, paradoxically, it may act as either a tumor suppressor or an oncoprotein…”
BackgroundTrends in Colorectal Cancer Mortality in the United States, 1999 - 2020
Kusnik, A. T., Renjithlal, S. L. M., Chodos, A., Shanmukhappa, S. C., Eid, M. M., Renjith, K. M., & Alweis, R. L. (2023) · Gastroenterology Research · doi:10.14740/gr1631 · Cited by 32 · cited 1×
“However, with 153,000 new cases annually and 52,500 deaths, CRC is the third-leading cause of cancer-related deaths among men and women combined in the U.S. [2].”
BackgroundSubbiah, V., Khawaja, M. R., Hong, D. S., Amini, B., Yungfang, J., Liu, H., Johnson, A., Schrock, A. B., Ali, S. M., Sun, J. X., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90380 · Cited by 30 · cited 1×
“…EGFR1-3, TIE2 (angiopoietin receptor), platelet-derived growth factor receptor β (PDGFR-β ), FGFR, KIT, RET, and BRAF [56], is approved for the treatment of refractory mCRC [57] and, in combination with cetuximab, displays potential for overcoming acquired resistance to anti-EGFR therapy [58].”
BackgroundReceipt of Targeted Therapy and Survival Outcomes in Patients with Metastatic Colorectal Cancer
Koroukian, S. M., Booker, B. D., Vu, L., Schumacher, F. R., Rose, J., Cooper, G. S., Selfridge, J. E., & Markt, S. C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.50030 · Cited by 27 · cited 1×
“Numerous factors undoubtedly contribute to improved survival in mCRC; however, precision targeting based on the specific mutational profiles of individual CRC tumors is playing an important role [12].”
BackgroundKoyama, K., Ishikawa, H., Abe, M., Shiose, Y., Ueno, S., Qiu, Y., Nakamaru, K., & Murakami, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267027 · Cited by 27 · cited 1×
“Multiple antibody therapies are in development targeting HER3 [40] including patritumab deruxtecan that includes an anti-HER3 mAb linked to a topoisomerase 1 (Top1) inhibitor payload [41].”
BackgroundTanjak, P., Chaiboonchoe, A., Suwatthanarak, T., Acharayothin, O., Thanormjit, K., Chanthercrob, J., Suwatthanarak, T., Wannasuphaphol, B., Chumchuen, K., Suktitipat, B., et al. (2023) · Cancers · doi:10.3390/cancers15041098 · Cited by 27 · cited 2×
“…microenvironment [24] and the lack of response of mCRC originating via the rather than Activating mutations in KRAS may also contribute to an immunosuppressive tumor microenvironment [24] and the lack of response of mCRC originating via the CIN pathway rather than the MSI pathway. the MSI pathway.”
BackgroundKortüm, B., Radhakrishnan, H., Zincke, F., Sachse, C., Burock, S., Keilholz, U., Dahlmann, M., Walther, W., Dittmar, G., Kobelt, D., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02407-6 · Cited by 26 · cited 1×
“Recently, niclosamide and two other β -catenin inhibitors (FH535 [116] and LF3 [117]) have been shown to downregulate MACC1-regulated S100A4 expression to decrease CRC propensity for metastatic progression [118].”
BackgroundA narrative review of genetic factors affecting fluoropyrimidine toxicity
Gmeiner, W. H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-17 · Cited by 25 · cited 1×
“Adjuvant chemotherapy is administered to reduce the risk for disease recurrence in CRC patients undergoing surgical resection for primary colon cancer with curative intent [131].”
BackgroundSelf-citationNon‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer
Osumi, H., Shinozaki, E., Wakatsuki, T., Suenaga, M., Ichimura, T., Ogura, M., Takahari, D., Ooki, A., Suzuki, T., Ota, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32320 · Cited by 25 · cited 1×
“BRAF V600E mutation is associated with decreased median survival, only 13.5 months relative to 30.6 months for BRAF wild-type tumors [4], while non-V600E BRAF mutations did not serve as a factor for poor prognosis in mCRC [91].”
BackgroundInfluentialLi, Y., Chen, X., Li, W., Ye, Y., Du, X., Sun, S., Liu, L., & Zhang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684309 · Cited by 24 · cited 1×
“…for patients progressing following treatment with front-line chemotherapy+BEV [125], while regorafenib whose targets include VEGF-R1, VEGF-R2, and VEGF-R3 or Fruquintinib is used in combination with TAS-102 (combination of trifluridine and Tiperacil) for third-line treatment [128].”
BackgroundHopirtean, C., & Nagy, V. M. (2017) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-881 · Cited by 22 · cited 2×
“…several drugs targeting angiogenesis display activity in mCRC, including ramucirumab, a humanized mAb targeting VEGF-R2; regorafenib, which inhibits multiple RTKs; and aflibercept, a recombinant fusion protein that serves as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor [125].”
BackgroundKim, S. T., Kim, S. Y., Lee, J., Yun, S. H., Kim, H. C., Lee, W. Y., Kim, T. W., Hong, Y. S., Lim, S.-B., Baek, J. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02962 · Cited by 21 · cited 1×
“However, oxaliplatin chemotherapy is associated with peripheral neuropathy, and strategies to limit the duration of oxaliplatin treatment in the adjuvant setting are being investigated to reduce toxicity without compromising efficacy [133].”
BackgroundGmeiner, W. H., Dominijanni, A., Haber, A. O., Ghiraldeli, L. P., Caudell, D. L., D’Agostino, R., Pasche, B. C., Smith, T. L., Deng, Z., Kiren, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0516 · Cited by 21 · cited 2×
“The long-established role for FP chemotherapy in CRC treatment holds promise for new FPs, including CF10, a polymeric fluoropyrimidine [145], to further advance the survival benefit of this important drug class in mCRC.”
BackgroundSelf-citationHER3 Alterations in Cancer and Potential Clinical Implications
Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T. (2022) · Cancers · doi:10.3390/cancers14246174 · Cited by 21 · cited 1×
“…displays intrinsically low kinase activity and must dimerize with either another EGFR-family member, including HER2 and EGFR, or a non-EGFR receptor tyrosine kinase (RTKs), including fibroblast growth factor receptor (FGFR), MET, or Axl to stimulate cell survival and proliferation signaling [38].”
BackgroundKullmann, F., Strissel, P. L., Strick, R., Stoehr, R., Eckstein, M., Bertz, S., Wullich, B., Sikic, D., Wach, S., Taubert, H., et al. (2023) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207855 · Cited by 20 · cited 1×
“Deficiencies in MMR are detected using a consensus marker panel (Bethesda panel) and immunohistochemistry (IHC), although a more rapid PCR method using seven markers of MSI (Idylla MSI assay) appears promising [130].”
MethodRAL GTPases mediate EGFR-driven intestinal stem cell proliferation and tumourigenesis
Nászai, M., Bellec, K., Yu, Y., Román‐Fernández, Á., Sandilands, E., Johansson, J., Campbell, A. D., Norman, J. C., Sansom, O. J., Bryant, D. M., et al. (2021) · eLife · doi:10.7554/elife.63807 · Cited by 20 · cited 1×
“RAL proteins activate EGFR/MAPK signaling [108] in the intestine in Drosophila, but a role in human CRC development is not established.”
Backgrounddel Carmen, S., Corchete, L. A., Gervas, R., Rodriguez, A., Garcia, M., Álcazar, J. A., García, J., Bengoechea, O., Muñoz-Bellvis, L., Sayagués, J. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61688-7 · Cited by 18
Gmeiner, W. H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s242224 · Cited by 18
Self-citationScott, A. J., Basu Mallick, A., Dotan, E., Cohen, S. J., Gold, P. J., Hochster, H. S., Subramaniam, S., Barzi, A., Watts, G. S., Blatchford, P. J., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0169 · Cited by 18 · cited 1×
“The combination of anti-MET therapy using a multi-tyrosine kinase inhibitor cabozantinib [51] or tepotinib [52] with anti-EGFR therapy may be effective in patients with acquired resistance to anti-EGFR therapy through MET amplification [53] (Figure 1).”
MethodLiu, T., Jiang, S., Teng, X., Zhong, L., Liu, M., Jin, Y., & Dong, M. (2023) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2022.2112222 · Cited by 17 · cited 2×
“Cetuximab and panitumumab treatment results in similar Although not common, the use of these mAbs may be associated with adverse reactions with decreased paronychia (nail infection) observed with panitumumab [30]. survival benefit.”
BackgroundJia, J., Morse, M. A., Nagy, R. J., Lanman, R. B., & Strickler, J. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00305 · Cited by 17 · cited 1×
“The combination of anti-MET therapy using a multi-tyrosine kinase inhibitor cabozantinib [51] or tepotinib [52] with anti-EGFR therapy may be effective in patients with acquired resistance to anti-EGFR therapy through MET amplification [53] (Figure 1).”
MethodFernández Montes, A., Alonso Orduña, V., Asensio Martínez, E., Rodríguez Salas, N., Torres, E., Cacho Lavín, D., Rodríguez Alonso, R. M., Falcó, E., Oliva, J. C., Cirera, L., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad117 · Cited by 17
TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells
Kim, J., Oh, J., Peterson, H. M., Carlson, J. C. T., Pittet, M. J., & Weissleder, R. (2022) · Advanced Biology · doi:10.1002/adbi.202200030 · Cited by 14 · cited 1×
“The TNIK inhibitor NCB0846 as well as the FDA-approved mebendazole that targets TNIK display promising activity in preclinical CRC models demonstrating the therapeutic potential of Wnt-pathway targeting for CRC treatment [111].”
BackgroundVoutsadakis, I. A. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100746 · Cited by 14 · cited 1×
“Published genomic studies show that 7.5% of mCRC patients with MSS tumor display high TMB, and sequencing may identify candidates for ICB therapy not detected based on dMMR/MSI [147].”
BackgroundInfluentialRedefining Colorectal Cancer by Tumor Biology
Salem, M. E., Puccini, A., & Tie, J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279867 · Cited by 14 · cited 1×
“…European Society for Medical Oncology (ESMO) to select patients for anti-EGFR 3 of 19 (comprehensive RAS panel) and BRAF mutations is recommended by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) to select patients for anti-EGFR therapy [23].”
BackgroundRathore, M., Zhang, W., Wright, M., Bhattacharya, R., Fan, F., Vaziri-Gohar, A., Winter, J., Wang, Z., Markowitz, S. D., Willis, J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0633 · Cited by 14 · cited 1×
“HER3 was also shown to be upregulated in CRC cells in response to factors secreted from liver endothelial cells (ECs), and blocking HER3 using a humanized anti-HER3 mAb seribantumab inhibited EC-induced CRC survival [39].”
BackgroundYoshino, T., Taieb, J., Kuboki, Y., Pfeiffer, P., Kumar, A., & Hochster, H. S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146137 · Cited by 12 · cited 1×
“TAS-102, a combination of trifluridine and a thymidine phosphorylase inhibitor (Tiperacil), was shown to improve OS relative to placebo [144].”
BackgroundFan, F., Ghosh, S., Powell, R. T., Roszik, J., Park, Y., Sobieski, M. M., Sorokin, A. V., STEPHAN, C. C., Kopetz, S., Ellis, L. M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281063 · Cited by 10 · cited 1×
“…of MEK inhibition led to studies investigating complementary pathways to potentially enhance MEK inhibition resulting in the identification of Src inhibition with dasatinib as a potential effective combination treatment; but in vivo studies have not yet been successful with this approach [87].”
BackgroundCirculating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer
Tie, J., Lo, S., & Gibbs, P. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2209374 · Cited by 9 · cited 1×
“Circulating tumor DNA (ctDNA) is emerging as a predictive factor for the necessity of adjuvant chemotherapy, and the use of ctDNA is expected to inform standard practice in the near future, potentially reducing toxicity due to unnecessary chemotherapy [134,135].”
BackgroundMetastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib
Yanagisawa, A., Kinehara, Y., Kijima, R., Tanaka, M., Ninomiya, R., Jokoji, R., & Tachibana, I. (2023) · Internal Medicine · doi:10.2169/internalmedicine.0002-22 · Cited by 7 · cited 2×
“…CRC); strategies targeting EGFR are central to the treatment of liver metastatic disease (Figure 2 EGFR is frequently overexpressed but is rarely mutated in CRC, and tyrosine kinase inhibitors (TKIs) targeting mutant-selective EGFR are not effective as single agents for mCRC treatment [28].”
BackgroundCibler HER2 dans le cancer colorectal
Spitzer, E., Cervera, P., André, T., & Cohen, R. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.01.013 · Cited by 7 · cited 1×
“The National Comprehensive Cancer Network recommends the systematic evaluation of HER2 status in determining mCRC treatment, and multiple new approaches to target HER2 overexpression in mCRC are in clinical development [36].”
BackgroundTabernero, J., Van Cutsem, E., Prausová, J., Isambert, N., Neuzillet, C., Siena, S., Pietrantonio, F., Falk, S., Wainberg, Z. A., Raghav, K. P. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.tps149 · Cited by 4 · cited 1×
“The combination of anti-MET therapy using a multi-tyrosine kinase inhibitor cabozantinib [51] or tepotinib [52] with anti-EGFR therapy may be effective in patients with acquired resistance to anti-EGFR therapy through MET amplification [53] (Figure 1).”
MethodMorano, F., & Pietrantonio, F. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.33488 · Cited by 3 · cited 1×
“…to anti-EGFR therapy can result from acquired mutations in downstream signaling pathways (RAS/RAF/MAPK and PI3K/AKT/mTOR) with one study finding that 28.6% of patients showed activating alterations in either a RAS protein, BRAF, ERK, or an alternative receptor tyrosine kinase receptor (RTK) [59].”
BackgroundInfluentialKrishnan, T., Ullah, S., Piantadosi, C., Karapetis, C. S., Townsend, A. R., Roy, A., Geerinckx, B., Maddern, G., Roder, D., Padbury, R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.4_suppl.42 · Cited by 2 · cited 1×
“In front-line treatment for mCRC, anti-VEGF therapy was shown to be comparable with anti-EGFR therapy when either was combined with chemotherapy [126], and while some previous studies indicated that chemotherapy was more effective in right-sided CRC [127], no side dependence was detected.”
ResultArbuck (1989) · doi:10.1002/1097-0142(19890315)63:6+<1036::aid-cncr2820631309>3.0.co;2-k · cited 1×
“The introduction of 5-FU and its modulation with leucovorin (LV) resulted in a substantial benefit in overall survival, 3–6 months [137].”
Background
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Activating mutations in the RAS/RAF/MEK/ERK signaling pathway downstream of EGFR generally confer resistance to anti-EGFR therapies; however, recent developments have led to new approaches for therapeutically targeting CRC with RAS or BRAF mutations [29].”
InfluentialTardito, S., Matis, S., Zocchi, M. R., Benelli, R., & Poggi, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137131 · Cited by 34
Biohybrid Microrobot Enteric‐Coated Microcapsule for Oral Treatment of Colorectal Cancer
Kang, Y., She, Y., Zang, Y., Yuan, M., Niu, G., Tian, X., Zhang, L., Lin, J., Yang, M., Pei, Z., et al. (2025) · Advanced Materials · doi:10.1002/adma.202420586 · Cited by 31
Lopez, B. A. A., Pinto-Colmenarez, R., Caliwag, F. M. C., Ponce-Lujan, L., Madera, M. D. F., Cortés, A. V. G., Martínez, A. G. M., Martinez, I. G. Z., & León, F. G. (2024) · Cureus · doi:10.7759/cureus.70933 · Cited by 31
“Still, further research is needed to evaluate these treatments [75-77].”
BackgroundOkechukwu, C. C., Ma, X., Sah, N., Mani, C., Palle, K., & Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16071360 · Cited by 23
Self-citation
Metadata
- Authors
- Gmeiner, W. H.
- Affiliations
- Wake Forest University Health Sciences (US)
- Corresponding author
- Gmeiner, William H.
- ORCID
- Gmeiner, William H.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-03-02
- Volume
- 16
- Issue
- 5
- Pages
- 1029
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10930828
- OpenAlex
- W4392375125
- Cited by
- 78
- References
- 150
- Citations by year
- 2026: 27 · 2025: 37 · 2024: 14
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- NIH-NCI (R42 CA254843-02A1, P30 CA 012197, CA200460)
- Department of Defense Peer Reviewed Cancer Research Program (R42 CA254843-02A1, P30 CA 012197, CA200460)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, metastatic colorectal cancer, anti-EGFR therapy, RAS/MAPK pathway, BRAF mutation, compensatory signaling, fluoropyrimidine chemotherapy, precision oncology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.